Announced
Completed
Financials
Tags
Majority
United States
Private
Friendly
healthcare
Health Care Services
Acquisition
Single Bidder
Domestic
Completed
Synopsis
Integra LifeSciences, a global medical device manufacturing company, completed the acquisition of Acclarent, a developer of technology for ENT related illnesses, from Ethicon, a manufacturer of surgical sutures and wound closure devices, and Johnson & Johnson, a pharmaceutical company, for $280m. “This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives. We are looking forward to welcoming the Acclarent employees to the Integra team. Together, we can make a profound impact on the future of ENT and neurosurgery,” Jan De Witte, Integra LifeSciences President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.